机构：[1]Department of Anesthesiology, Peking University People’s Hospital, Beijing, China,[2]Department of Anesthesiology, First Affiliated Hospital of Kunming Medical University, Kunming, China外科科室麻醉手术科（医技）昆明医科大学附属第一医院
As the most commonly used endocrine therapy regimen for patients with hormone receptor-positive (HR+) breast cancer (BC) at present, aromatase inhibitors (AIs) reduce the risk of localized and distant recurrence, contralateral BC and secondary cancer, and prolong disease-free survival. Clinical data show that poor adherence during AI treatment is mainly attributed to muscle and joint pain, fatigue, anxiety, depression and sleep disturbances during treatment. The rapid decline of estrogen caused by AIs in a short period of time enhances sympathetic activity, activates T cells in the body, produces inflammatory factors such as tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and interleukin (IL)-17A, and promotes the occurrence of inflammation and bone loss. This article reviewed the mechanism of poor dependence on AIs in BC patients from the neuro-immuno-endocrine (NIE) perspective and provided clues for clinical intervention against poor adherence.
第一作者机构：[1]Department of Anesthesiology, Peking University People’s Hospital, Beijing, China,
通讯作者：
推荐引用方式(GB/T 7714)：
Huifang Li,Jie Gao,Yi Feng.Neuro-immune-endocrine mechanisms with poor adherence to aromatase inhibitor therapy in breast cancer[J].FRONTIERS IN ONCOLOGY.2022,12:doi:10.3389/fonc.2022.1054086.
APA：
Huifang, Li,Jie, Gao&Yi, Feng.(2022).Neuro-immune-endocrine mechanisms with poor adherence to aromatase inhibitor therapy in breast cancer.FRONTIERS IN ONCOLOGY,12,
MLA：
Huifang, Li,et al."Neuro-immune-endocrine mechanisms with poor adherence to aromatase inhibitor therapy in breast cancer".FRONTIERS IN ONCOLOGY 12.(2022)
